SM
AVIR icon

SG3 Management’s Atea Pharmaceuticals AVIR Stock Holding History

SG3 Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,000
Closed -$46.8K – 1037
2021
Q3 		$105K Buy
+3,000
New +$83.2K ﹤0.01% 857

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SG3 Management's AVIR Position: Q4 2021 in Review

SG3 Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2021, closing a stake of 3,000 shares — an estimated $46.8K sold.

SG3 Management first reported a position in AVIR in Q3 2021 and held it in 1 quarter. The position peaked at $105K in Q3 2021. 143 funds tracked by Wall St. Rank hold AVIR as of Q4 2021.

  • SG3 Management reported no remaining Atea Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 3,000 Atea Pharmaceuticals shares in Q4 2021, an estimated $46.8K.
  • SG3 Management first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • SG3 Management's Atea Pharmaceuticals position peaked at $105K in Q3 2021.
  • 143 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.